While federal prior authorization reform legislation has yet to make it over the finish line and be enacted into law, state governments continue to pass legislation to mitigate the burdensome ...

“This is the first randomized phase 3 trial in patients with stage III and high-risk stage II colon cancer to demonstrate that post-treatment exercise is both achievable and effective in improving ...

ASCO Perspective Quote “The pace of therapeutic advances in upper gastrointestinal cancers has accelerated in recent years. Now, the MATTERHORN trial shows that perioperative treatment with FLOT plus ...

CHICAGO — Results from a large, prospective cohort study show that eating a less inflammatory diet may reduce the risk of death for patients with stage III colon cancer. The research will be presented ...

CHICAGO — Results from an international clinical trial show that a 14-gene molecular assay can help identify patients with early-stage non-squamous non-small cell lung cancer (NSCLC) who could benefit ...

CHICAGO — Results from an international phase 3 study show that the targeted therapy combination of encorafenib and cetuximab with mFOLFOX6 chemotherapy helps patients with BRAF V600E -mutant ...

ALEXANDRIA, Va. — Results from a multinational study found that using artificial intelligence (AI) assistance can help pathologists more accurately classify breast cancers with low levels of HER2 ...

ALEXANDRIA, Va. — A large observational study of more than 170,000 patients with diabetes and obesity in the United States has found that GLP-1 receptor agonists may modestly reduce the risk of ...

ASCO Perspective Quote “Immunotherapy has improved survival outcomes for patients with extensive-stage small cell lung cancer (ES-SCLC), marking meaningful progress in a historically challenging ...

ALEXANDRIA, Va., and SUNNYVALE, Calif. – The American Society of Clinical Oncology (ASCO) and Google Cloud today announced a powerful collaboration to launch an AI-based ASCO Guidelines Assistant.

CMS has proposed a Calendar Year (CY) 2023 physician conversion factor of $33.0775. This represents a 4.4% reduction from the 2022 physician conversion factor of $34.6062. This reduction is largely a ...

Published ahead of print July 28, 2021 DOI: 10.1200/OP.21.00438 Robin T. Zon, Erin B. Kennedy, Kerin Adelson, Sibel Blau, Natalie Dickson, David Gill, Nicole Laferriere, Ana Maria Lopez, Therese M.